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Abstract 
Background: Prescribing, dispensing and administering pro re nata (PRN; as needed 
or necessary, as determined by an individual) medicines to people with intermittent or 
short-term conditions is a potential area for medication errors and inappropriate 
prescribing and administration. In people with dementia, regular PRN medicines use 
can demonstrate good practice when appropriate or poor in situations where their use 
is not recommended. However, the frequency of PRN prescription and administration 
within long-term care settings (care homes) for people with dementia is largely 
unknown. A limited number of studies worldwide suggest variation between 
countries. 
Objective: To describe the prescription and administration rates of PRN medicines for 
people with dementia in UK care homes. 
Setting: Fifty UK care homes. 
Method: Medication details were collected from review of residents’ medicines 
records within the care home for the previous month. 
Main outcome measure: Prescription and administration of PRN medicines for the 
treatment of behaviours associated with neuropsychiatric symptoms and pain.  
Results: The most commonly prescribed PRN medicines were analgesics (35.3%), 
although lower levels of PRN prescription were observed compared to recent studies. 
The percentage of residents receiving PRN administrations varied, with 20% for 
antipsychotics, 50% for benzodiazepines, 59% for analgesics, and 85.7% for 
nonbenzodiazepine hypnotics being administered. 
Conclusion: Further research is needed to understand the decision making in PRN 
prescription and administration within long-term care. The prescribing of potentially 
inappropriate medicines remains a problem in long-term care settings and pharmacists 
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have a key role in reducing inappropriate polypharmacy by undertaking medication 
reviews that consider both regular and PRN medicines. 
 
Impact on practice 
• There are inconsistencies in practice for people living with dementia and 
memory problems in care homes, and regular medication reviews are required.  
• Nonpharmacological alternatives should be considered for the management of 
neuropsychological symptoms for people living with dementia and memory 
problems.  
• Particular attention should be given to ensure appropriate antipsychotic 
prescription for people with dementia and memory problems in care homes. 
Antipsychotics should only be used where absolutely necessary, and only in 
the short term. 
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Pro re nata prescribing and administration for neuropsychiatric symptoms and 
pain in long-term care residents with dementia and memory problems: a cross-
sectional study 
Introduction 
Dementia affects approximately 47 million people worldwide, and this is projected to 
rise [1]. Around 20-40% of people with dementia live in long-term care [2,3]. 
Multimorbidity (having more than one long term condition) [4] and thus 
polypharmacy (taking multiple medicines; often defined as ≥ 4 medicines [5]) is 
highly prevalent and concerning in long-term care, with 91% of long-term care 
residents taking 5+ medicines [5]. A study conducted in England suggested that risks 
of polypharmacy include multiple side effects, increased risk of preventable 
hospitalisations, impaired quality of life, increased likelihood of interactions between 
medicines [4] and higher risks of medication errors, which are common in this 
population [6,7]. In addition, inappropriate (over or under) prescribing, is 
commonplace [8] with implications for health and well-being and associated cost 
burden to the healthcare system. On average, 50% (range 24% to 80%) of people 
living in long-term care receive at least one inappropriate medicine and up to 30% of 
residents with advanced dementia are prescribed medicines classified as ‘never 
appropriate’ for this population [9]. Therefore, understanding the prescription and 
administration of medicines for residents in long-term care is a clinical and policy 
imperative.  
PRN medicines in long-term care 
Prescribing, dispensing and administering pro re nata (PRN; as needed or necessary, 
as determined by an individual) medicines to people with intermittent or short-term 
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conditions is a potential area for medication errors and inappropriate 
prescribing/administration. PRN medicines are given when an individual requires 
them, rather than as a regular daily dose or at specific times e.g. during a medication 
round [10]. Long-term care residents with dementia who may have impaired 
communication rely on staff making accurate and timely judgements of need for 
administration of PRN medicines. For example, those with impaired communication 
or who have difficulties taking medicines have been noted to receive less PRN 
medicines [11]. As a result, guidelines have been developed aimed at improving 
appropriate assessment and administration of PRN medicines in long-term care 
settings [12,13].  
Alongside warranted variations in PRN administration between residents, 
unwarranted variations between long-term care settings exist, suggesting PRN use 
may not be based on individual resident needs, but organisation level factors, such as 
staffing levels and care home size [11,14] and staff confidence or knowledge to make 
judgments about the necessity for PRN medicine administration [16]. The absence of 
clear instructions for staff on how and when to administer medicines increases the 
likelihood of adverse events or errors [12]. Therefore, PRN medicines administration 
may be a signal of underlying care culture and quality and a risk factor in poorer 
quality care settings. 
In people with dementia, regular PRN medicines use can demonstrate good practice 
when appropriate (e.g. PRN administration of appropriate analgesics may indicate 
effective assessment and management of acute or intermittent pain) or poor practice 
(e.g. PRN administration of antipsychotics may indicate use as a first rather than last 
resort for managing agitation). This is of concern given the increased risks of these 
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drugs for falls, stroke and death [16] and their recommendation for use only in the 
short term, if closely monitored and after all psychosocial approaches have been 
exhausted [17]. Frequent administration of PRN medicines such as pain relief 
however, may indicate the need for a medication review as a PRN prescription may 
be inappropriate. For example, antipsychotics should be limited to residents who are 
severely distressed or at risk of harming themselves or others, and where non-
pharmacological interventions have failed. Whilst antipsychotics have proven modest 
efficacy, side effects can be disabling and they increase the risk of cognitive decline, 
stroke and death [18]. Likewise the use of certain non-benzodiazepine hypnotics 
known as Z drugs has been found to increase of bone fractures and death [19]. 
Therefore prescription and administration of medicines such as anti-psychotics, 
benzodiazepines, non-benzodiazepines, hypnotics and analgesia to people with 
dementia are of particular interest as they present potential high risks for well-being, 
quality of life and safety if administered incorrectly or not according to need.  
However, the frequency of PRN prescription and administration within long-term care 
settings (care homes) is largely unknown. A limited number of studies worldwide 
suggest variation between countries. PRN prescription rates in care homes range from 
91% in the USA [20] and 75% in Germany [21] to just 31% in Norway [22]. 
Significant within-country variations also exist: three studies conducted in Australian 
long-term care settings found overall PRN prescription rates of 94% [23], 84% [11] 
and 7% [24]. Other studies have examined PRN medicine prescribing on a specific 
drug type basis. For example, the frequency of antipsychotic PRN prescription was 
24.5% in a Canadian study [25], 23% in an Australian study [26], and 37% [27] and 
15% [28] in two German studies. Analgesic prescribing on a PRN basis ranges from 
40% in Germany [29], 48% in the USA [30], and 72% in Norway [31]. Where 
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reported, the most commonly prescribed PRN medicines are analgesics 
[20,21,23,32,33] or anxiolytics/hypnotics [24]. 
Administration levels also vary; one US study reported administration rates of 30% 
over 7 days, while two Australian studies reported rates of 54% [11] and 28% [23]. 
Individual medication-type PRN administrations also varied: administrations of 
analgesia were 30% in the USA [20] but only 12% in Norway [31]. Antipsychotic 
PRN administration rates are generally low. A Canadian study reported only 2.1 PRN 
administrations on average per resident per month, with most residents receiving no 
administrations [25]. In an Australian study, 11% of residents received at least one 
administration in a month [26], whilst in Germany this figure was just 6% [28].  
Within the existing literature, two studies were specifically conducted with people 
living with dementia [20,24] and dementia prevalence within the remaining samples 
ranged from 54-98.5% [26, 31]. Where this was examined those with a PRN 
prescription were more likely to have dementia ([28], 61% vs 39% [34]). However, 
one study [33] found no difference in the likelihood of PRN prescription in residents 
with and without dementia. Therefore, little is known about the prescribing or 
administration of PRN medicines to people living with dementia in UK care homes. 
In the present study, we were interested in the clinically significant class of PRN 
medicines related to the management of neuropsychiatric symptoms and pain, which 
if not managed can lead to neuropsychiatric symptoms [35]. Pain assessment and 
management for people with dementia is frequently suboptimal [29]. Despite known 
risks, and evidence suggesting widespread prescription but variable degrees of 
administration of PRN medicines, there is very limited understanding of PRN 
medication use in care homes for people living with dementia [36]. 
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Aim of the study 
We aimed to provide the first reported data on the rates of prescription and 
administration of PRN medicines associated with neuropsychiatric symptoms and 
pain management for people living with dementia and memory problems in UK long-
term care settings (care homes). 
Ethics approval 
Ethical approval for the [name redacted] trial was gained from the Yorkshire and the 
Humber Leeds Bradford NHS REC (reference number [redacted]). Consent from 
study participants included permission to reanalyse data for research purposes. Ethical 
approval for this sub-study was granted by [redacted] University Research Ethics 
Committee.   
Method 
Data analysed in this paper was collected as part of the [name redacted], a UK 
randomised controlled trial in care homes. The trial aimed to establish the 
effectiveness of a person-centred intervention for the quality of life of people living 
with dementia or memory problems. Baseline data (collected from May 2014 – 
December 2015) on prescribed and administered medication were analysed for this 
paper. 
Participants 
Participants were recruited from 50 care homes in the United Kingdom. Residents 
with dementia diagnoses or memory problems (i.e. without a confirmed dementia 
diagnosis) were eligible to participate. Residents formally admitted to an end of life 
care pathway or who only resided semi-permanently were ineligible.  
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Procedure 
Care homes were selected by listing all potentially eligible care homes across the 
three recruitment areas (West Yorkshire, Oxfordshire and South London) using 
publicly available data. They were then randomly ordered within post-code 
area/boroughs and the first 10-12 listed care homes approached from one post-
code/borough in each hub. This method rotated across each postcode/borough until 
sufficient homes were recruited. Approach was initially made by post, followed by a 
researcher phone call. Eligibility was confirmed for any homes potentially interested 
in participation ahead of consent. Care homes were recruited randomly, stratified by 
postcode, size, and type. Homes subject to regulatory enforcement or who were 
deemed ‘inadequate’ by the UK quality regulator (the Care Quality Commission) 
were ineligible to participate. 
Medication details were collected from residents’ medicine administration records for 
the previous month, held within their care home. Prescription of medicines relevant to 
the management of neuropsychiatric symptoms associated with dementia, physical 
and psychological health problems (e.g. antipsychotic, benzodiazepine, mood 
stabiliser) and pain (analgesic) and frequency of administration of these if prescribed 
on a PRN basis, was recorded on a standardised form by researchers. Demographic 
data including comorbidities was collected from resident care records. 
Additionally, information about symptoms of agitation was collected using the 
Cohen-Mansfield Agitation Inventory (CMAI [37]), which measures 29 behaviours 
typically associated with agitation/aggression. Staff members identified the frequency 
of 29 behaviours during the previous two weeks, rated on a seven-point Likert scale 
(1-7) ranging from “never” to “several times an hour”. This measure shows moderate 
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concurrent validity with scores on the Neuropsychiatric Inventory – Nursing Home 
version Agitation sub-scale (r = .52 [38]). 
Statistical Analysis 
We calculated descriptive data (counts and means) by resident and care home. To 
explore our hypothesis that individual care home approach to medicines use were 
related to rates of PRN administration, we calculated Pearson’s correlation 
coefficients using SPSS version 25.  
Results 
Demographic Characteristics 
A total of 728 participants were recruited from 50 care homes (31 residential or 
nursing home, 19 dementia care specialist home). Care homes provided care for an 
average of 31.8 residents, with an average of 77.7% of residents having dementia (see 
Table 1 for participant demographics). Participants had, on average, two 
comorbidities alongside dementia (range 0 – 14). Selected comorbidities often 
associated with PRN prescriptions included depression (n = 117, 16.1%), anxiety (n = 
57, 7.9%), psychosis (n = 40, 5.5%), sleep disturbance (n = 13, 1.8%), and delirium (n 
= 5, 0.7%). Demographic data were missing for two participants who were not 
included in analyses, providing a total of 726 participants. 
Medication Use 
The total number of regular medicines prescribed per resident ranged from 0 to 28 
(Mean = 8.68, SD = 4.14) with 0-3 on a PRN basis (Mean = 0.4, SD = .60). Eight 
residents (0.1%) were not prescribed any medicines. The total number of medication 
prescriptions was 6,266, of these 5,949 (95.0%) were regularly prescribed and 317 
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(5.0%) prescribed on a PRN basis. The prevalence of regularly and PRN prescribed 
medicines is shown in Table 2, stratified by gender, age and regular medication 
prescription, in line with previous reporting [21,22]. 
The most frequently prescribed PRN medication were analgesics with over a third of 
participants (35.3%) prescribed them (see Table 3 for breakdown of type of 
medication prescribed). All other PRN prescriptions were at very low levels, ranging 
from 0.4% for mood stabilisers to 5.4% for benzodiazepines. The class/individual 
medicines prescribed and administered can be seen in Table 4. 
Correlation analyses 
Neither the total number of prescribed medicines (r = .03, p >.05), nor the number of 
PRN medicines administered (r = .14, p >.05) correlated with care home. 
Level of agitation (as measured by the CMAI), was associated with total number of 
PRN prescriptions (r = .08, p < .05), but not total number of regular and PRN 
prescriptions (r = -.06, p > .05). 
Discussion 
The current study presented the first evidence on PRN medication prescribing and 
administration within UK long-term care settings (care homes) for people with 
dementia. The most commonly prescribed PRN medicines were analgesics, in line 
with most recent evidence [21]. However, this may not be universally positive as 
many staff members lack the skills to perform adequate pain assessments, meaning 
residents do not always receive analgesic medicines when needed [30]. This is 
particularly important as cognitive impairment is associated with decreased likelihood 
of receiving PRN analgesics [31]. In addition, continuing potentially inappropriate 
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long-term PRN analgesics without review, for example nonsteroidal anti-
inflammatory drugs (NSAIDs), may mask or cause potentially harmful interactions or 
adverse effects [39,40]. Regular and PRN NSAIDs can cause peptic ulcer disease, 
may increase thrombotic risk and impair renal function with the potential for Acute 
Kidney Injury. NSAIDs also interact with many commonly prescribed medicines, 
including antihypertensives, antithrombotics, lithium and Selective Serotonin 
Reuptake Inhibitors [41]. Unfortunately, we did not collect data on the underlying 
reasons why medications were prescribed (see study limitations). We therefore cannot 
rule out the possibility that staff behaviours relating to PRN use for people with 
dementia increase exposure to potentially inappropriate medications with an 
unfavourable balance of benefits and harms, when compared to alternative treatment 
options. More research is needed to ascertain the degree to which a diagnosis of 
dementia modifies the probability of meeting STOPP (Screening Tool of Older 
Person’s Prescriptions) or Beers criteria or not benefiting from START (Screening 
Tool to Alert doctors to Right Treatment) criteria [39,40].   
Our data was collected after publication of guidance on antipsychotic medication 
prescribing for people with dementia within the UK [12]. This suggested 
antipsychotic medication should be used as a last resort, and not longer than 6 weeks 
at a time. Within our sample, 1.4% had a prescription for an antipsychotic medication 
on a PRN basis and 12.7% on a regular basis. However, we cannot know whether the 
levels observed are specific to our sample without drawing comparisons to other care 
home samples within the UK. Only one study has considered both regular and PRN 
antipsychotic use, where Managers reported that 8% of residents had a regular and 
4% of residents had a PRN antipsychotic prescription [42], however caution should be 
exercised in interpreting this self-reported data from managers. The study also did not 
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report how frequently prescribed PRN medications were administered. As our data 
were cross-sectional we do not know how long regular antipsychotic medicines had 
been prescribed. A low level of PRN antipsychotic prescriptions was reported in a 
recent Australian study [23], although their seven-day data collection period included 
only one administration on average, whereas within our sample, there were two 
administrations across one month. This may reflect recent increased understanding 
about the potential harms of antipsychotic administration for people living with 
dementia [23] or the presence of good practice guidelines for care homes to work with 
[12,13]. Whilst we observed generally low levels of PRN prescriptions and 
administrations, it is not known whether this is in response to the guidelines, as no 
evidence exists for the prevalence of PRN prescriptions in the UK before their 
development.  
PRN medication administration varied within the present study. For some categories, 
such as antipsychotics, only 2 of 10 residents received an administration within the 
one-month data collection period. Other categories, such as benzodiazepines and non-
benzodiazepine hypnotics, were far more common. For example, 50% of participants 
prescribed these on a PRN basis received at least one administration during the 
month. However, some residents received over 100 administrations of 
benzodiazepines and non-benzodiazepine hypnotics within the data collection period. 
Such under and over exploitation of possibilities suggests inappropriate PRN 
prescriptions for some residents and should trigger the need for a medication review. 
For example, a regular dose may have been warranted. Additionally, this may indicate 
a trend of prescribing benzodiazepines and other sedating drugs in place of 
antipsychotics, given the drivers to reduce the prescription of the latter in people with 
dementia, which is of concern. In addition to antipsychotics and benzodiazepines, 
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other medicines that were prescribed would be deemed potentially inappropriate, 
particularly in people with dementia. For example, tricyclic antidepressants, 
paroxetine and fluoxetine [39,40]. Future research should explore this as there are 
clear guidelines regarding the long-term use of benzodiazepines within this 
population [43]. This is due to issues around dependency, toxicity, cognitive decline, 
falls and increased sensitivity towards side effects such as delirium [44,45]. The needs 
of long-term care residents should be regularly reviewed to ensure only required 
medicines are prescribed and administered and that PRN prescriptions remain 
appropriate [6]. This is particularly important for those with dementia, as individuals 
with more severe cognitive impairment were less likely to receive pain relief on a 
PRN basis [20,31] possibly as they struggle to communicate their symptoms [23], or 
expressions of pain through behaviours such as agitation are attributed as a symptom 
of dementia [46]. However, in our study, we found that there was a weak but 
significant relationship between number of PRN prescriptions and scores on an 
agitation measure. Further research is needed to understand this relationship and how 
well understood the needs of individuals experiencing agitation are. 
Previous research suggests the main predictor of PRN medication is often the care 
home in which the resident lives [11]. We found the likelihood of being prescribed 
PRN medicines did not differ by care home. This could be because PRN prescriptions 
for some categories (i.e. antipsychotics) were too small to generate significant 
differences, rather than a lack of differences. 
Our research implies that PRN use is lower than anticipated, but the current research 
base does not allow us to state, with confidence, that this is a genuine shift in 
expected prescription and administration. Future research should seek to collate the 
datasets from several large-scale clinical trials that have recently been completed in 
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the UK, to establish whether this pattern of lower prescribing is seen more widely, 
before establishing whether a general trend towards lower PRN prescriptions for 
people with dementia is being seen generally.  
Strengths and limitations 
This study presented the first examination of PRN medication prescription and 
administration within UK care homes for people with dementia. Whilst the data are 
cross-sectional, they provide an overview of current prescribing practices. Although, 
we do not know whether as dementia progresses, individuals are more likely to 
receive prescriptions for PRN medicines. Existing evidence suggests that as residents 
spend longer in care homes, their likelihood of receiving a PRN prescription increases 
[21]. Future work should seek to examine changes in prescriptions and 
administrations over time and their association with harms in care homes, such as 
falls and hospitalisations. Our data only included those falls resulting in 
hospitalisation. We are unlikely to have captured their true extent, and so analysing 
this data would have been inappropriate. Furthermore, whilst we have data on 
frequency of administrations, we do not have dosage or reason for prescription, which 
limited interpretation of the appropriateness of prescriptions. Heterogeneous data 
collection and research questions mean drawing comparisons between our findings 
and those of similar existing studies may be inappropriate. 
Conclusion 
For the first time in the UK, this study presented the first evidence of the prescription 
and administration of PRN medicines for neuropsychiatric symptoms and pain 
management for people living with dementia. Generally, low levels of prescriptions 
and even lower levels of administrations were observed for the management of 
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neuropsychiatric symptoms. This could be viewed positively as non-pharmacological 
treatments for dementia are being encouraged. However, the variation seen in PRN 
administrations suggests more research is needed to understand UK practices. The 
prescribing of potentially inappropriate medicines remains a problem in long-term 
care and pharmacists have a key role in reducing inappropriate polypharmacy by 
undertaking medication reviews that consider both regular and PRN medicines. 
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Age at registration (years) M(SD) 85.6 (7.64) 
Gender  
Female 536 (73.8%) 
Male 190 (26.2%) 
Length of stay in care home (years) M(SD)  2.3 (2.34) 
Ethnicity   
White British/European 702 (96.7%) 
Other 24 (3.3%) 
Funding type  
Local Authority 352 (48.5%) 
Self-funded 289 (39.8%) 
Local Authority & Self-funded 34 (4.7%) 
Continuing Healthcare 48 (6.6%) 
Missing 3 (0.4%) 
Dementia severity (Measured by  
Functional Assessment Staging Tool)  
 
1-3 6 (1%) 
4 95 (13.6%) 
5 74 (10.6%) 
6 380 (54.5%) 
7 142 (20.4%) 
Missing 29 (3.9%) 
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Table 2. Pro re nata (PRN) prescribing for residents in care homes stratified by demographic characteristics (N = 726) 
 No PRN medicine 1 PRN medicine 2 PRN medicines 3 PRN medicines 
Age     
<70 21 (70) 7 (23) 2 (7) - 
70-79 86 (64) 37 (28) 9 (7) 2 (1) 
80-89 232 (67) 93 (27) 19 (5) 4 (1) 
≥90 130 (61) 68 (32) 14 (7) 2 (<1) 
All 469 (65) 205 (28) 44 (6) 8 (1) 
Gender     
Female 332 (62) 182 (34) 20 (4) 2 (<1) 
Male 137 (72) 44 (23) 6 (3) 3 (2) 
Regular prescriptions      
M (SD) range 8.03 (4.11) 0 - 28 8.72 (3.92) 1-23 8.81 (3.69) 3-17 8.60 (5.08) 4-16 
0-4 92 (69) 37 (29) 2 (1) 2 (1) 
5-9 230 (66) 102 (30) 14 (4) 1 (<1) 
≥10 147 (60) 87 (35) 10 (4) 2 (1) 
 
Note: all numbers provided as N(% of category) unless otherwise specified
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Table 3. Prevalence of prescribed and administered regular and PRN medicines 
(N=726) 




N (%) medicines 
administered of 
prescribed 
Number of administrations per 
resident of those administered 
at least once over a month 
[M (SD) range] 
Antipsychotic     
Regular 93 (12.8) 96 - - 
PRN 10 (1.4) 10 2 (20) 4.14 (8.30) 0 - 22 
Benzodiazepine     
Regular 43 (6.0) 47 - - 
PRN 38 (5.4) 39 19 (50) 18.62 (35.84) 0 - 137 
Non-benzodiazepine hypnotic     
Regular 40 (5.5) 40 - - 
PRN 6 (1.0) 6 5 (85.7) 28.83 (47.30) 0 - 123 
Antidepressant     
Regular 268 (37.0) 299 - - 
PRN 3 (0.4) 3 3 (100) 31 (41.87) 2 - 79 
Cognition enhancing medicines     
Regular 171 (23.6) 177 - - 
Anticonvulsants     
Regular 35 (4.8) 40 - - 
Mood stabilisers     
Regular 3 (0.4) 3 - - 
Analgesic     
Regular 356 (50.1) 468 - - 
PRN 256 (35.3) 259 151 (58.3) 25.14 (36.43) 0 - 122 
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Antipsychotic 106 96 10 
Amisulpride 6 5 1 
Aripriprazole 5 5 - 
Chloropromazine 1 1 - 
Flupentixol 3 3 - 
Haloperidol 4 4 3 
Levomepromazine 2 - 2 
Olanzapine 17 17 - 
Prochlorperazine 2 1 1 
Quetiapine 19 19 - 
Risperidone 43 40 2 
Benzodiazepine 86 47 39 
Clonazepam 2 2 - 
Diazepam 24 13 11 
Lorazepam 46 19 27 
Midazolam 1 1 - 
Nitrazepam 4 4 - 
Oxazepam 1 1 - 
Temazepam 8 7 1 
Non-benzodiazepine hypnotic 46 40 6 
Chlormethiazole 1 - 1 
Melatonin 1 1 - 
Zopiclone 44 39 5 
Antidepressant 302 299 3 
Amitriptyline 18 18 - 
Citalopram 88 88 - 
Dosulepin 1 1 - 
Duloxetine 2 2 - 
Escitalopram 2 2 - 
Fluoxetine 9 9 - 
Lofepramine 3 3 - 
Mirtazapine 80 80 - 
Paroxetine 2 2 - 
Sertraline 26 26 - 
Trazodone 61 58 3 
Venlafaxine 7 7 - 
Cognition enhancing medicines 177 177 - 
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Donepezil 87 87 - 
Galantamine 19 19 - 
Memantine 55 55 - 
Rivastigmine 16 16 - 
Anticonvulsants 40 40 - 
Carbamazepine 10 10 - 
Gabapentin 2 2 - 
Lamotrigine 1 1 - 
Levetiracetam 7 7 - 
Phenobarbital 3 3 - 
Phenytoin 2 2 - 
Pregabalin 1 1 - 
Sodium Valproate 12 12 - 
Topiramate 1 1 - 
Mood stablisers 3 3 - 
Lithium 3 3 - 
Analgesic 724 468 256 
Aspirin 102 101 1 
Buprenorphine 21 21 - 
Co-codamol 55 34 21 
Codeine 42 27 15 
Ibuprofen 23 18 5 
Morphine 13 6 7 
Paracetamol 447 243 204 
Tramadol 9 8 1 
Other 12 10 2 
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